All In Biotech

Drug Trial Radar · NCT04169672

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

A Phase II, Open-label, Single-arm, Multi-center Study of the Efficacy and Safety of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Mar 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

248

Actual

Start

Dec 26, 2019

Primary completion

Feb 28, 2023

Study completion Feb 28, 2023

Sponsor

Lead sponsor
Hutchison Medipharma LimitedIndustry
Sponsor type
Industry
First posted
Nov 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Surufatinib single agent or Surufatinib combined with Toripalimab in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SurufatinibDrug

    Surufatinib is a tablet in the form of 50mg, oral, once a day.

  • ToripalimabDrug

    Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs) of safety run-in partTime frame: From Cycle 1 Day 1 to the end of Cycle 2 Day 7 (each cycle is 21 days)
  2. Objective response rate (ORR)Time frame: From date of first dose of study drug until disease progression, withdrawal of consent, death, new anti-cancer therapy(up to approximately 2 years)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.